Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Design Therapeutics Inc. develops small-molecule gene targeted chimeras (GeneTAC®) to treat inherited nucleotide repeat expansion diseases. Its platform modulates gene expression by targeting specific DNA sequences, aiming to restore normal cellular function. Core programs include treatments for Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy type-1, and Huntington's disease. The company focuses on disease-modifying therapies with broad tissue distribution, leveraging proprietary chemistry for scalable, targeted genomic medicines.
This description was generated via AI from an annual report. Updated about 1 year ago.